{"created":"2023-05-15T14:36:14.425511+00:00","id":46651,"links":{},"metadata":{"_buckets":{"deposit":"4e95fb4f-100b-4e76-bc28-861465bcb1fa"},"_deposit":{"created_by":1,"id":"46651","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"46651"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00046651","sets":["1"]},"author_link":["465069","465068","465064","465061","465072","465062","465067","465066","465071","465073","465065","465070","465060","465063","465074"],"item_8_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2012-11","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"5","bibliographicPageEnd":"30","bibliographicPageStart":"624","bibliographicVolumeNumber":"96","bibliographic_titles":[{"bibliographic_title":"International Journal of Hematology"}]}]},"item_8_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"High-dose chemotherapy followed by autologous stem cell transplantation (auto-SCT) is widely used as a salvage therapy in the treatment of refractory malignant lymphoma. To investigate the safety and feasibility of a high-dose MCNU, carboplatin, etoposide and cyclophosphamide (MCVC) regimen, we conducted a prospective multicenter trial. Thirty patients with relapsed/refractory/poor-risk non-Hodgkin lymphoma (NHL n = 27) or Hodgkin lymphoma (HD n = 3) were uniformly treated with an MCVC regimen and underwent auto-SCT. The median follow-up duration of the surviving patients was 67 months (56-133 months). The major toxicities were anorexia (94 %), diarrhea (80 %), nausea (79 %), febrile neutropenia (70 %), alopecia (67 %) and mucositis (60 %). Three patients developed severe left ventricular dysfunction, and two patients developed severe sinusoidal obstructive syndrome (SOS). Of these patients, two died without disease progression. Treatment-related mortality was 6.6 %. Late-onset adverse events including two cases of cytomegalovirus pneumonia and one of interstitial pneumonia were observed. In DLBCL (n = 13) and transformed FL (n = 2) patients, OS and EFS at 3 years were 72 and 46 %, respectively. These results suggest that the MCVC regimen followed by auto-SCT is a feasible and tolerable therapy for relapsed/refractory malignant lymphoma. However, cardiac toxicity due to high-dose cyclophosphamide and development of SOS can occur and should be carefully monitored. Further follow-up is needed to evaluate the long-term efficacy and safety of this regimen.","subitem_description_type":"Abstract"}]},"item_8_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0925-5710","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Kameoka, Yoshihio"}],"nameIdentifiers":[{"nameIdentifier":"465060","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Takahashi, Naoto"}],"nameIdentifiers":[{"nameIdentifier":"465061","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ishizawa, Keniti"}],"nameIdentifiers":[{"nameIdentifier":"465062","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kato, Yuichi"}],"nameIdentifiers":[{"nameIdentifier":"465063","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ito, Jugo"}],"nameIdentifiers":[{"nameIdentifier":"465064","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sasaki, Osamu"}],"nameIdentifiers":[{"nameIdentifier":"465065","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Murai, Katzunori"}],"nameIdentifiers":[{"nameIdentifier":"465066","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Noji, Hideyoshi"}],"nameIdentifiers":[{"nameIdentifier":"465067","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hirokawa, Makoto"}],"nameIdentifiers":[{"nameIdentifier":"465068","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tajima, Katsushi"}],"nameIdentifiers":[{"nameIdentifier":"465069","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Shichishima, Tsutomu"}],"nameIdentifiers":[{"nameIdentifier":"465070","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ishida, Yoji"}],"nameIdentifiers":[{"nameIdentifier":"465071","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Harigae, Hideo"}],"nameIdentifiers":[{"nameIdentifier":"465072","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sawada, Kenichi"}],"nameIdentifiers":[{"nameIdentifier":"465073","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"田嶋 克史","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"465074","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Safety and feasibility of high-dose ranimustine(MCNU), carboplatin, etoposide, and cyclophosphamide(MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Safety and feasibility of high-dose ranimustine(MCNU), carboplatin, etoposide, and cyclophosphamide(MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma."}]},"item_type_id":"8","owner":"1","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2013-12-02"},"publish_date":"2013-12-02","publish_status":"0","recid":"46651","relation_version_is_last":true,"title":["Safety and feasibility of high-dose ranimustine(MCNU), carboplatin, etoposide, and cyclophosphamide(MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma."],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T23:49:14.312004+00:00"}